NRx Pharmaceuticals (NRXP) Projected to Post Earnings on Friday

NRx Pharmaceuticals (NASDAQ:NRXP) is expected to post its Q4 2025 results before the market opens on Friday, March 13th. Analysts expect NRx Pharmaceuticals to post earnings of ($0.09) per share and revenue of $7.5250 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

NRx Pharmaceuticals Trading Up 4.6%

Shares of NASDAQ NRXP opened at $1.81 on Wednesday. The firm’s 50-day moving average price is $2.05 and its 200-day moving average price is $2.48. NRx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $3.84. The stock has a market capitalization of $57.68 million, a price-to-earnings ratio of -0.77 and a beta of 1.97.

Analysts Set New Price Targets

Several analysts have recently weighed in on NRXP shares. HC Wainwright lifted their target price on NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. D. Boral Capital reissued a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Monday. Ascendiant Capital Markets reissued a “buy” rating and issued a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Finally, Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Institutional Trading of NRx Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP boosted its position in shares of NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the period. State Street Corp lifted its stake in NRx Pharmaceuticals by 14.0% in the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after acquiring an additional 10,700 shares during the last quarter. Geode Capital Management LLC grew its holdings in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after acquiring an additional 37,598 shares in the last quarter. Commonwealth Equity Services LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $994,000. Finally, Vanguard Group Inc. raised its holdings in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.